



MacroGenics, Inc.  
 Investor Relations Department  
 9640 MEDICAL CENTER DRIVE  
 Rockville, MD 20850  
 United States

Visit IR website [↗](#)  
 Sign-up for Email alerts [↗](#)

**NASDAQ: MGNX**

Last Trade:	18.99
Trade Time:	1:44 PM ET Dec 13, 2017
Change:	0.51 <span style="color: green;">▲</span> (+2.760%)
Day Range	18.39 - 19.12
52-Week Range	14.36 - 23.47
Volume	195,291

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases. The company generates its pipeline of product candidates from its proprietary suite of next-generation antibody-based technology platforms. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceu... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- Dec 11, 2017 [Phase 1 Data for Flotetuzumab, MacroGenics' CD123 x CD3 DART® Molecule, Presented at 59th Annual ASH Meeting](#)
- Dec 5, 2017 [MacroGenics Announces Closing of MGA012 Global Collaboration and License Agreement with Incyte](#)
- Nov 15, 2017 [MacroGenics Names Dr. Jay Siegel to its Board of Directors](#)
- Nov 13, 2017 [MacroGenics to Participate in Two Upcoming Investor Conferences](#)
- Nov 10, 2017 [MacroGenics Announces Poster Presentations at 32nd Annual SITC Meeting 2017](#)

## Financials [\[ View all \]](#)

- [Third Quarter Financial Results](#)
- Feb 28, 2017 [Annual Report \(10-K\)](#)
- Apr 4, 2017 [Proxy Statement \(DEF 14A\)](#)
- Nov 8, 2017 [Quarterly Report \(10-Q\)](#)
- Aug 2, 2017 [Quarterly Report \(10-Q\)](#)
- May 3, 2017 [Quarterly Report \(10-Q\)](#)